Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Organisation › Details

Cosmo Pharmaceuticals N.V. (SIX: COPN)

Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. The current growth drivers, including the state-of-the-art GI Genius™ intelligent endoscopy system that enhances polyp detection rates during colonoscopy and the prescription drug Winlevi® to treat acne are generating substantial revenue streams. The Company’s proprietary MMX® technology enables targeted delivery of active ingredients in the colon and is a cornerstone of its product development. Cosmo also has a robust clinical development pipeline, which includes Breezula® for the treatment of androgenetic alopecia. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company currently has approximately 300 employees, all dedicated to making a significant impact in the field of healthcare. *

 

Period Start 2016-03-01 established
  Group Cosmo Pharmaceuticals (Group)
  Predecessor Cosmo Pharmaceuticals S.A.
Product Industry gastrointestinal drug
Persons Person Della Chà, Alessandro (Cosmo Pharmaceuticals 202404– Board Chair before CEO)
  Person 2 Donnelly, Niall (Cosmo Pharmaceuticals 201607 CFO)
     
Region Region Dublin
  Country Ireland, Republic of
  Street Sir John Rogerson’s Quay
Riverside II
  City Dublin 2
  Tel +353-1-817-0370
    Address record changed: 2020-12-02
     
Basic data Employees D: 101 to 500 (2024-09-23)
  Currency EUR
  Annual sales 67,664,000 (revenue, total, consolidated (2016) 2016-12-31)
  Profit 19,340,000 (2016-12-31)
  Cash 117,649,000 (2016-12-31)
     
    * Document for »About Section«: Cosmo Pharmaceuticals N.V.. (9/23/24). "Press Release: Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development". Dublin.
     
   
Record changed: 2024-09-30

Advertisement

Picture Berlin Partner Top News Aignostics Mayo Clinic Pathology 650x200px

More documents for Cosmo Pharmaceuticals (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x300px




» top